Dr. Satish Stephen Maharaj, MD

Dr. Maharaj practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Maharaj's NPI, 1285084558, was assigned on June 17, 2016. Dr. Maharaj graduated from University of the West Indies Faculty of Medicine in 2013. Dr. Maharaj holds Florida license ME166540.

Dr. Maharaj's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Maharaj's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Maharaj is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Maharaj to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Maharaj practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Maharaj's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Maharaj is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Maharaj's licenses on file in 3 states: Florida, Texas and Kentucky.

Dmand AI lists chronic embolism thrombosis and colorectal cancer among the conditions Dr. Maharaj treats.

CMS data shows 267 Medicare services from Dr. Maharaj across 4 procedure codes in 2024, for 117 Medicare patients. Medicare paid $25,203 for them.

CMS counts 117 Medicare patients who saw Dr. Maharaj in 2024. The largest group is 65 to 74, with 67 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Maharaj's median patient age at 68, with 42% women.

In 2024, Dr. Maharaj wrote 369 Medicare Part D claims for 116 patients. 90% of them were for generic drugs. CMS names the drug for 219 of them, across 8 drugs with 11 or more claims each, at $24,727 in total drug cost. In 2023, CMS named 171 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Maharaj for performance year 2024, reported as part of a group. Dr. Maharaj accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Maharaj as offering telehealth.

Dmand AI links 57 papers to Dr. Maharaj, published from 2011 to 2025. 2017 was the busiest year, with 14. The most frequent topics are Echocardiography, Cardiac Tamponade and Lupus Erythematosus, Systemic. Dr. Maharaj has published most often in EJHaem. Dr. Maharaj's most frequent co-authors are Simone M. Chang, MD, Karan Seegobin, MD and Cherisse Melissa Baldeo, MD.

CMS Open Payments shows 247 general payments to Dr. Maharaj from 46 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 98% of the total. Amgen Inc. paid the most, $1,270.

Dmand AI lists 4 awards for Dr. Maharaj, most recently Hematology Oncology Fellow Award in 2022.

Dr. Maharaj graduated from University of the West Indies Faculty of Medicine in 2013. Dr. Maharaj is a member of ACP, ASCO, ASH and CMDA.

Dr. Maharaj is in network with 18 carriers, including Elevance, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 12. Check the plan with the practice before a visit.